Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi


10.1016/j.ctro.2020.04.006

http://scihub22266oqcxt.onion/10.1016/j.ctro.2020.04.006
suck pdf from google scholar
32373721!7193092!32373721
unlimited free pdf from europmc32373721    free
PDF from PMC    free
html from PMC    free
PDF vom PMID32373721 :   free

suck abstract from ncbi

pmid32373721
Nephropedia Template TP

gab.com Text

Twit Text FOAVip

Twit Text #

English Wikipedia


  • Low dose lung radiotherapy for COVID-19 pneumonia The rationale for a cost-effective anti-inflammatory treatment #MMPMID32373721
  • Lara PC; Burgos J; Macias D
  • Clin Transl Radiat Oncol 2020[Jul]; 23 (ä): 27-29 PMID32373721show ga
  • The COVID-19 pandemia is affecting people worldwide. Most of the patients suffered of a respiratory disease that will progress to an acute respiratory distress syndrome (ARDS). SARS-CoV-2 pneumonia severely ill patients, develop a systemic inflammatory response with a Cytokine Release Syndrome (CRS), that is characterized by a sudden increase in several pro-inflammatory cytokines, mainly IL-1, IL-6 and TNF-alfa by activated macrophages (M1 phenotype). Blocking IL-6 with tocilizumab and using respirator equipment seems to be a very important issue in this (SARS-CoV-2) pneumonia, but not all patients are referred to such treatments. Low dose radiotherapy (0,5 Gy), is an evidence-based anti-inflammatory treatment, that could modify the immune landscape in the lung affected of SARS-CoV-2 pneumonia, through macrophages polarization to alternatively activated Macrophages (M2 phenotype). Radiation-induced cancer risk could be assumed due to the very low dose used, the advanced age of the patients and the life-threatening condition of SARS-Cov2 pneumonia. LDRT is a cost-effective non-toxic treatment already available in most general hospitals. This fact allows that it would be used for the large number of patients that will suffer this disease, and that would not receive specific anti-IL-6 treatments in ICUs in low and middle income countries.
  • ä


  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    27 ä.23 2020